Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Jabil Likely To Report Lowe Q2 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Published 15/03/2024, 05:47
© Reuters.  Jabil Likely To Report Lowe Q2 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
JBL
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

Jabil Inc. (NYSE: JBL) is expected to release earnings results for its second quarter, before the opening bell on March 15, 2024.

Analysts expect the Saint Petersburg, Florida-based company to report quarterly earnings at $1.66 per share, down from $1.88 per share in the year-ago period. Jabil is projected to report quarterly revenue of $6.89 billion, according to data from Benzinga Pro.

On Jan. 25, Jabil announced that its board declared a quarterly dividend of 8 cents per share of common stock.

Jabil shares fell 0.9% to close at $147.46 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

  • Goldman Sachs analyst Mark Delaney maintained a Buy rating and raised the price target from $141 to $161 on March 4, 2024. This analyst has an accuracy rate of 74%.
  • Stifel analyst Matthew Sheerin maintained a Buy rating and boosted the price target from $135 to $140 on Dec. 15, 2023. This analyst has an accuracy rate of 77%.
  • JP Morgan analyst Samik Chatterjee maintained an Overweight rating and cut the price target from $150 to $146 on Nov. 29, 2023. This analyst has an accuracy rate of 72%.
  • Barclays analyst George Wang maintained an Overweight rating and cut the price target from $144 to $135 on Nov. 29, 2023. This analyst has an accuracy rate of 85%.
  • Raymond James analyst Melissa Fairbanks maintained a Strong Buy rating and boosted the price target from $120 to $160 on Oct. 11, 2023. This analyst has an accuracy rate of 80%.

Read This Next: Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.